Palantir Nearly Doubled Its Revenue. Its Stock Stood Still. Is It Time to Buy the Stock?

Palantir reported Q2 revenue growth of 93% year over year to $1.94 billion, while operating income more than tripled to $912 million and operating margin expanded 2,000bps to 47%. Management has raised its 2026 revenue target twice, to roughly $8.15 billion, and U.S. commercial remaining deal value rose 124% to $6.2 billion. However, despite its flat share price over the past year and a compressed sales multiple, Palantir still trades at about 52x guided sales and 76x forward earnings, leaving the stock vulnerable to any material growth deceleration.

Analysis

PLTR's setup is now a duration-risk trade rather than a near-term execution debate: sustained growth and margin conversion have been absorbed by the valuation, leaving little incremental upside unless estimates continue rising at an exceptional rate. At roughly 52x forward sales, a deceleration from hypergrowth toward even a still-elite 50-60% range could drive multiple compression faster than earnings revisions can offset it. The key near-term variable is whether U.S. commercial contract value converts into recognized revenue without materially lengthening implementation cycles or requiring higher sales-and-services investment.

Over the next 1-3 months, each earnings print is likely binary: another material guide-up can support the shares, but merely meeting guidance would challenge expectations embedded in the multiple. A 15-20% de-rating to 40-44x sales is plausible on evidence of slowing net-new commercial bookings, lower remaining-deal-value growth, or operating-margin reinvestment; that would outweigh a conventional earnings beat. Conversely, continued acceleration in commercial revenue and stable margins would make a short structurally dangerous given the limited free float available for valuation-sensitive investors and persistent AI benchmark demand.

The non-obvious beneficiary of PLTR's valuation discipline is NVDA: enterprise-AI budgets may be shifting from experimental model training toward deployment, where Palantir is a visible software layer, but deployment at scale still pulls inference compute. The contrarian view is that PLTR's high price may be less vulnerable than conventional SaaS comparables if it demonstrates a repeatable operating-system position in regulated government and industrial workflows; the missing proof is retention, expansion, and gross-margin durability across the newer commercial cohort.

For the 6-18 month horizon, the decisive issue is whether Palantir can retain software-like incremental economics as customer deployments broaden. Rising implementation labor, customer concentration, government budget delays, or procurement scrutiny would undermine the premise that revenue can compound while margins remain elevated. This is not a clean fundamental short until bookings and guidance cease confirming the growth narrative.

Key Decisions for Investors

• Maintain PLTR as underweight/avoid for long-only exposure above $176; require either a 25-30% pullback or two quarters of durable commercial growth with no margin erosion before adding. The thesis is falsified by another material annual revenue guide-up accompanied by stable or improving operating margins.
• For tactical hedging over the next earnings cycle, consider a defined-risk PLTR put spread 2-4 months out, targeting a 15-20% downside move; size modestly because an upside guidance revision can produce a sharp squeeze. Use a close above the prior ~$208 high as a technical stop/hedge trigger.
• Prefer a relative-value expression: long NVDA / short PLTR in equal-dollar, beta-adjusted sizing for 1-3 months. This isolates enterprise-AI deployment spending while reducing exposure to PLTR's unusually demanding revenue multiple; exit if PLTR commercial bookings and full-year guidance accelerate again while NVDA inference demand disappoints.
• Add an earnings watch alert for remaining-deal-value growth, commercial net-new customer additions, and sales/implementation expense. A meaningful deceleration in any two metrics, even with an EPS beat, would strengthen the PLTR downside case; absent that evidence, do not press a short.